Cargando…
P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430916/ http://dx.doi.org/10.1097/01.HS9.0000971696.54506.b2 |
| _version_ | 1785091074370306048 |
|---|---|
| author | Spurgeon, Stephen Mei, Matthew Barr, Paul M. Barrientos, Jacqueline de Vos, Sven Furman, Richard Patel, Krish Thompson, Philip Choi, Michael Y. Kallam, Avyakta Wang, Siruo Ogbu, Uzor Marinello, Patricia Wang, Michael |
| author_facet | Spurgeon, Stephen Mei, Matthew Barr, Paul M. Barrientos, Jacqueline de Vos, Sven Furman, Richard Patel, Krish Thompson, Philip Choi, Michael Y. Kallam, Avyakta Wang, Siruo Ogbu, Uzor Marinello, Patricia Wang, Michael |
| author_sort | Spurgeon, Stephen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430916 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309162023-08-17 P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY Spurgeon, Stephen Mei, Matthew Barr, Paul M. Barrientos, Jacqueline de Vos, Sven Furman, Richard Patel, Krish Thompson, Philip Choi, Michael Y. Kallam, Avyakta Wang, Siruo Ogbu, Uzor Marinello, Patricia Wang, Michael Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430916/ http://dx.doi.org/10.1097/01.HS9.0000971696.54506.b2 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Spurgeon, Stephen Mei, Matthew Barr, Paul M. Barrientos, Jacqueline de Vos, Sven Furman, Richard Patel, Krish Thompson, Philip Choi, Michael Y. Kallam, Avyakta Wang, Siruo Ogbu, Uzor Marinello, Patricia Wang, Michael P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY |
| title | P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY |
| title_full | P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY |
| title_fullStr | P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY |
| title_full_unstemmed | P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY |
| title_short | P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY |
| title_sort | p1200: zilovertamab vedotin (mk-2140) in relapsed or refractory (r/r) non-hodgkin lymphoma (nhl): updated results from the phase 1 waveline-001 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430916/ http://dx.doi.org/10.1097/01.HS9.0000971696.54506.b2 |
| work_keys_str_mv | AT spurgeonstephen p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT meimatthew p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT barrpaulm p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT barrientosjacqueline p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT devossven p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT furmanrichard p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT patelkrish p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT thompsonphilip p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT choimichaely p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT kallamavyakta p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT wangsiruo p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT ogbuuzor p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT marinellopatricia p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study AT wangmichael p1200zilovertamabvedotinmk2140inrelapsedorrefractoryrrnonhodgkinlymphomanhlupdatedresultsfromthephase1waveline001study |